Empagliflozin Dosing for Cardiovascular and Renal Protection in Older Adults with Moderate CKD

Cardiovascular and Renal Efficacy

• In the EMPA‑REG OUTCOME randomized trial, empagliflozin 10 mg and 25 mg produced identical reductions in major adverse cardiovascular events, cardiovascular death, and heart‑failure hospitalization, demonstrating no dose‑response relationship for these outcomes. (High‑quality RCT evidence) 1
• The American College of Cardiology (ACC) recommends initiating empagliflozin at the lowest approved dose (10 mg daily) for cardiovascular risk reduction, stating that higher doses do not confer additional CV benefit. (Class I, Level A) 2
• All major cardiovascular and renal outcome trials used fixed doses of empagliflozin, confirming that the 10 mg dose delivers the full mortality‑reducing effect observed in these studies. (High‑quality trial data) 1, 2

Glycemic Control Considerations

• For an older adult with moderate chronic kidney disease, the recommended HbA1c target is ≤ 6.5 %; a value of 6.4 % already meets this goal, making further glucose‑lowering unnecessary and increasing hypoglycemia risk. (Guideline‑based target) 3, 4
• At an estimated glomerular filtration rate (eGFR) of ~44 mL/min/1.73 m², empagliflozin’s ability to lower glucose is markedly attenuated regardless of dose because renal glucose reabsorption inhibition becomes less effective as kidney function declines. (Pharmacologic limitation) 1

Renal Function and Dosing Guidance

• The FDA label specifies that empagliflozin dose adjustments are driven by glycemic efficacy, not safety concerns, and that cardiovascular benefits persist down to an eGFR of 30 mL/min/1.73 m² when the 10 mg dose is used. (Regulatory guidance) 1
• For patients with eGFR < 45 mL/min/1.73 m², the 10 mg dose remains appropriate for cardiovascular and renal protection; dose escalation for glycemic control is not recommended because glucose‑lowering efficacy is lost at lower kidney function. (Evidence‑based dosing) 1

Safety Profile at Higher Doses

• The 25 mg dose is associated with a higher rate of genital mycotic infections (≈ 6 % vs ≈ 4 % with 10 mg) and an increased risk of volume depletion, especially relevant in elderly patients with reduced renal function. (Trial safety data) 1

Clinical Recommendations (ACC Guidance)

• Maintain empagliflozin 10 mg once daily as the fixed dose for cardiorenal protection in older adults with moderate CKD. (Class I, Level A) 1, 2

• Do not increase to 25 mg because:

• Continue concurrent metformin at a dose adjusted for eGFR (e.g., 500 mg daily) as it remains appropriate for glycemic management in this renal range. (Standard practice) 1

• Monitor eGFR every 3–6 months and continue empagliflozin 10 mg even if eGFR falls below 45 mL/min/1.73 m², because cardiovascular and renal benefits persist at lower kidney function. (Evidence‑based monitoring) 1